TRAVERE THERAPEUTICS, INC. Deferred Tax Assets, Valuation Allowance
TRAVERE THERAPEUTICS, INC. (TVTX) had Deferred Tax Assets, Valuation Allowance of $370.65 million as of 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsValuationAllowance · last filed 2026-02-19
- 2025-12-31: Deferred Tax Assets, Valuation Allowance $370.65M.
- 2024-12-31: Deferred Tax Assets, Valuation Allowance $344.18M.
- 2023-12-31: Deferred Tax Assets, Valuation Allowance $290.68M.
- 2022-12-31: Deferred Tax Assets, Valuation Allowance $293.40M.
| Period end | Deferred Tax Assets, Valuation Allowance | Deferred Tax Assets, Valuation Allowance as first filed |
|---|---|---|
| 2025-12-31 | $370.65M 10-K · filed 2026-02-19 | |
| 2024-12-31 | $344.18M 10-K · filed 2026-02-19 | |
| 2023-12-31 | $290.68M 10-K · filed 2025-02-21 | |
| 2022-12-31 | $293.40M 10-K · filed 2024-02-20 | |
| 2021-12-31 | $198.30M 10-K · filed 2023-02-23 | |
| 2020-12-31 | $147.83M 10-K · filed 2022-02-24 | |
| 2019-12-31 | $84.75M 10-K · filed 2021-03-01 | |
| 2018-12-31 | $36.19M 10-K · filed 2020-02-24 | |
| 2017-12-31 | $27.62M 10-K · filed 2019-02-26 | |
| 2016-12-31 | $15.58M 10-K · filed 2018-07-06 | |
| 2015-12-31 | $6.98M 10-K · filed 2017-03-01 | |
| 2014-12-31 | $36.02M 10-K · filed 2016-02-26 | $36.02K 10-K · filed 2015-03-11 |
| 2013-12-31 | $12.04M 10-K/A · filed 2015-07-09 | -$11.71K 10-K · filed 2014-03-28 |
| 2012-12-31 | $1.91M 10-K/A · filed 2015-07-09 | -$1.96K 10-K · filed 2013-06-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |